<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27737403</article-id><article-id pub-id-type="pmc">5062707</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a
Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brand&#x000e3;o</surname><given-names>Paulo Gabriel Melo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Lobo</surname><given-names>Francisco Ricardo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Ramin</surname><given-names>Serginando Laudenir</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Sakr</surname><given-names>Yasser</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Mauricio Nassau</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lobo</surname><given-names>Suzana Margareth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Critical Care Medicine, Faculdade de Medicina
de S&#x000e3;o Jos&#x000e9; do Rio Preto (FAMERP), S&#x000e3;o Jos&#x000e9; do Rio
Preto, SP, Brazil.</aff><aff id="aff2"><label>2</label>Division of Anesthesiology, Department of Surgery,
Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto (FAMERP), S&#x000e3;o
Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><aff id="aff3"><label>3</label>Department of Anesthesiology and Intensive Care Medicine,
Friedrich-Schiller-University, Jena, Germany.</aff><aff id="aff4"><label>4</label>Division of Cardiology. Faculdade de Medicina de
S&#x000e3;o Jos&#x000e9; do Rio Preto (FAMERP), S&#x000e3;o Jos&#x000e9; do Rio Preto,
SP, Brazil.</aff><author-notes><corresp id="c1"><bold>Correspondence Address:</bold> Suzana Margareth Lobo,
Faculdade de Medicina de S&#x000e3;o Jos&#x000e9; do Rio Preto, Av. Faria Lima,
5416 - Vila S&#x000e3;o Pedro, S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil
Zip code: 15090-000. E-mail: <email>suzanaalobo@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>May-Jun</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>May-Jun</season><year>2016</year></pub-date><volume>31</volume><issue>3</issue><fpage>213</fpage><lpage>218</lpage><history><date date-type="received"><day>02</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>OBJECTIVE:</title><p>&#x003b1;-<sub>2</sub>-agonists cause sympathetic inhibition combined with
parasympathetic activation and have other properties that could be
beneficial during cardiac anesthesia. We evaluated the effects of
dexmedetomidine as an anesthetic adjuvant compared to a control group during
cardiac surgery.</p></sec><sec><title>METHODS:</title><p>We performed a retrospective analysis of prospectively collected data from
all adult patients (&#x0003e; 18 years old) undergoing cardiac surgery. Patients
were divided into two groups, regarding the use of dexmedetomidine as an
adjuvant intraoperatively (DEX group) and a control group who did not
receive &#x003b1;-<sub>2</sub>-agonist (CON group).</p></sec><sec><title>RESULTS:</title><p>A total of 1302 patients who underwent cardiac surgery, either coronary
artery bypass graft or valve surgery, were included; 796 in the DEX group
and 506 in the CON group. Need for reoperation (2% <italic>vs.</italic>
2.8%, <italic>P</italic>=0.001), type 1 neurological injury (2%
<italic>vs.</italic> 4.7%, <italic>P</italic>=0.005) and prolonged
hospitalization (3.1% <italic>vs.</italic> 7.3%, <italic>P</italic>=0.001)
were significantly less frequent in the DEX group than in the CON group.
Thirty-day mortality rates were 3.4% in the DEX group and 9.7% in the CON
group (<italic>P</italic>&#x0003c;0.001). Using multivariable Cox regression
analysis with in hospital death as the dependent variable, dexmedetomidine
was independently associated with a lower risk of 30-day mortality (odds
ratio [OR]=0.39, 95% confidence interval [CI]: 0.24-0.65,
<italic>P</italic>&#x02264;0.001). The Logistic EuroSCORE (OR=1.05, 95% CI:
1.02-1.10, <italic>P</italic>=0.004) and age (OR=1.03, 95% CI: 1.01-1.06,
<italic>P</italic>=0.003) were independently associated with a higher
risk of 30-day mortality.</p></sec><sec><title>CONCLUSION:</title><p>Dexmedetomidine used as an anesthetic adjuvant was associated with better
outcomes in patients undergoing coronary artery bypass graft and valve
surgery. Randomized prospective controlled trials are warranted to confirm
our results.</p></sec></abstract><kwd-group><kwd>Dexmedetomidine</kwd><kwd>Cardiovascular Surgical Procedures</kwd><kwd>Adjuvants</kwd><kwd>Anesthesia</kwd></kwd-group></article-meta></front><body><p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Abbreviations, acronyms &#x00026;
symbols</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CABG</td><td rowspan="1" colspan="1">= Coronary artery bypass graft</td></tr><tr><td rowspan="1" colspan="1">CI</td><td rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td rowspan="1" colspan="1">CON</td><td rowspan="1" colspan="1">= Control</td></tr><tr><td rowspan="1" colspan="1">CPB</td><td rowspan="1" colspan="1">= Cardiopulmonary bypass</td></tr><tr><td rowspan="1" colspan="1">DEX</td><td rowspan="1" colspan="1">= Dexmedetomidine</td></tr><tr><td rowspan="1" colspan="1">IABP</td><td rowspan="1" colspan="1">= Intra-aortic balloon pump</td></tr><tr><td rowspan="1" colspan="1">ICU</td><td rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td rowspan="1" colspan="1">IQ</td><td rowspan="1" colspan="1">= Interquartile range</td></tr><tr><td rowspan="1" colspan="1">MAC</td><td rowspan="1" colspan="1">= Minimal alveolar concentration</td></tr><tr><td rowspan="1" colspan="1">OR</td><td rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td rowspan="1" colspan="1">SD</td><td rowspan="1" colspan="1">= Standard deviation</td></tr></tbody></table></table-wrap>
</p><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiac anesthesia has changed over the years from using high doses of opioids to
fast-track surgery. High doses of opioids were justified based on the hemodynamic
stability provided even in patients with marginal cardiac reserve<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>, but resulted in patients requiring
prolonged mechanical ventilation support. Limited financial resources and a shortage
of intensive care unit (ICU) beds have increased the need to optimize treatment and
avoid complications in the postoperative period. Fasttrack cardiac anesthesia uses
methods, such as short acting neuromuscular blockers, low-doses of opioids or
regional anesthesia, with the intention of speeding up weaning from ventilation and
decreasing ICU length of stay<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.
Fast-track cardiac anesthesia is being adopted more and more widely to reduce ICU
bed use and hospital costs associated with postoperative care<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r5" ref-type="bibr">5</xref>]</sup>. The safety and ability of this approach to diminish time on
the ventilator have been demonstrated recently in a large cohort of almost 8000
patients<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Use of
anesthetic adjuvants with opioids sparing qualities may create alternatives that
accelerate weaning from mechanical ventilation and patients recovery.</p><p>Many beneficial effects of &#x003b1;-<sub>2</sub>-agonists have been reported,
including a decrease in sympathetic tone with attenuation of hemodynamic and
neuroendocrine responses to stress<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> and reduced anesthetic and opioid requirements<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Dexmedetomidine has analgesic,
sedative, anxiolytic and sympatholytic properties. Patients in the ICU sedated with
dexmedetomidine alone wake when requested, become cooperative and the drug does not
cause respiratory depression<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.
Herr et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> demonstrated the
safety and benefits of using dexmedetomidine in comparison to propofol sedation in
the postoperative period of coronary artery bypass graft (CABG) surgery. In a
double-blind randomized study, Jalonen et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> compared dexmedetomidine to fentanyl as an anesthesia
adjunct during CABG. They reported reduced sympathetic tone, attenuated hyperdynamic
responses with dexmedetomidine and a reduction on additional fentanyl doses during
the operation before bypass and postoperatively<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>The primary aim of our study was to evaluate the effects of dexmedetomidine as an
anesthetic adjuvant during CABG and valve surgery on mortality and on the length of
stay in the ICU compared to a control group receiving general balanced
anesthesia.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This study was a retrospective analysis of an electronic database with data
prospectively collected from January 2003 to April 2011. The data were retrieved
from the databank collected for a previously published study registered in Clinical
Trials.gov (NCT00780845) by one of the authors (MNM)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Because of the retrospective nature of the
study, the need for written informed consent was waived by the local ethics
committee.</p><p>Either propofol (2 mg/kg) or etomidate (0.2 mg/kg) were used for anesthesia
induction. Isoflurane was used in minimal alveolar concentration (MAC) range of
0.8-1.2 for anesthetic maintenance in both groups, depending on the anesthetic depth
required. Neuromuscular block was achieved with an infusion of atracurium at 8
&#x000b5;g/kg/min. The anesthetic adjuvant was used at the discretion of the
anesthesiologist, according to his/her experience. Patients were divided into two
groups according to whether they had received dexmedetomidine (DEX group), given as
a loading dose of 0.5 &#x000b5;g/kg over 20 minutes for anesthesia induction and a
maintenance infusion of 0.5 &#x000b5;g/kg/h, or a control group (CON group) technique
without anesthetic adjuvant. Both groups could receive doses of fentanyl as
necessary (bolus of 1-5 &#x000b5;g/kg).</p><p>The preoperative estimation for risk of hospital death was calculated using the
Logistic EuroSCORE<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Left
ventricular ejection fraction was estimated for each patient using M-mode
echocardiography based on the cubed or Teicholz method, wall motion scoring, or
biplane Simpson's methods, or ventricular angiography. Data were collected on time
on cardiopulmonary bypass (CPB), need for dialysis or intra-aortic balloon pump
(IABP), mortality at 30 days and need for reintubation because of pulmonary
complications. Acute kidney injury was assessed based on the AKIN
classification<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Type 1
neurological injury was defined as a new episode of motor deficit, coma, seizure or
encephalic lesion documented by cranial computed tomography or magnetic resonance
imaging. Hospital mortality and hospital discharge dates were available for all
patients from electronic hospital records.</p><p>Data were analyzed using SPSS Statistical version 17 and StatsDirect Software version
2.7.8. Descriptive statistics were computed for all study variables. The
Kolmogorov-Smirnov test was used to verify the normality of distribution of
continuous variables. Non-parametric tests of comparison were used for variables
evaluated as not being normally distributed. Difference testing between groups was
performed using Mann-Whitney U, Chi-square and Fisher's exact tests as
appropriate.</p><p>A survival analysis was performed using Kaplan-Meier graphs at 30 days and the log
rank test was used to compare the survival curves. We performed a multivariable
logistic regression analysis with 30-day mortality as the dependent variable to
evaluate the possible influence of dexmedetomidine on 30-day mortality after
adjusting for possible confounders. In this analysis, we included age, gender, the
logistic EuroSCORE, body mass index, dexmedetomidine, CABG or valve surgery,
diabetes mellitus, moderate or severe left ventricular dysfunction, number of
grafts, on-pump CABG, duration of CPB and use of IABP. Colinearity was excluded
prior to modeling (R<sup>2</sup>&#x0003e;0.6 for all pairwise correlations). None of the
included variables was colinear. A Hosmer and Lemeshow test was performed to assess
the goodness of fit for the final model. In the case of categorical variables, a
reference category was defined. Odds ratios (OR) and 95% confidence intervals were
computed. Continuous variables are presented as mean &#x000b1; standard deviation
(SD) or median [25-75% interquartile range] (IQ) and categorical variables as number
and percentage unless otherwise indicated. All statistics were two-tailed, and a
<italic>P</italic>&#x0003c;0.05 was considered significant.</p></sec><sec sec-type="results"><title>RESULTS</title><p>We included 1302 consecutive patients who underwent CABG (n=817) or valve (n=485)
surgery during the study period (63% male; age =54.7&#x000b1;13.2 years): 796
patients in the DEX group and 506 patients in the CON group. The characteristics of
the study groups are shown in <xref ref-type="table" rid="t1">Table 1</xref>. The
overall 30-day hospital mortality was 5.8%.</p><p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>CON group (n=506)</bold></th><th align="center" rowspan="1" colspan="1"><bold>DEX group (n=796)</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Male (%)</td><td align="center" rowspan="1" colspan="1">312 (62)</td><td align="center" rowspan="1" colspan="1">506 (64)</td><td align="center" rowspan="1" colspan="1">0.487</td></tr><tr><td align="center" rowspan="1" colspan="1">Age, years; median [IQ]</td><td align="center" rowspan="1" colspan="1">58 [47-67]</td><td align="center" rowspan="1" colspan="1">56 [47-64]</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="center" rowspan="1" colspan="1">EuroSCORE (Additive)</td><td align="center" rowspan="1" colspan="1">3 (2-5)</td><td align="center" rowspan="1" colspan="1">3 (1-4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">EuroSCORE (Logistic)</td><td align="center" rowspan="1" colspan="1">4.0&#x000b1;5.4</td><td align="center" rowspan="1" colspan="1">2.8&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">110 (22)</td><td align="center" rowspan="1" colspan="1">174 (22)</td><td align="center" rowspan="1" colspan="1">0.959</td></tr><tr><td align="center" rowspan="1" colspan="1">Moderate/severe LVD</td><td align="center" rowspan="1" colspan="1">118 (23)</td><td align="center" rowspan="1" colspan="1">153 (19)</td><td align="center" rowspan="1" colspan="1">0.076</td></tr><tr><td align="center" rowspan="1" colspan="1">CABG n (%)</td><td align="center" rowspan="1" colspan="1">310 (61)</td><td align="center" rowspan="1" colspan="1">507 (64)</td><td align="center" rowspan="1" colspan="1">0.377</td></tr><tr><td align="center" rowspan="1" colspan="1">On-pump surgery n (%)</td><td align="center" rowspan="1" colspan="1">421 (83)</td><td align="center" rowspan="1" colspan="1">616 (77)</td><td align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" rowspan="1" colspan="1">Number of grafts</td><td align="center" rowspan="1" colspan="1">3 (2-3)</td><td align="center" rowspan="1" colspan="1">2 (2-3)</td><td align="center" rowspan="1" colspan="1">0.352</td></tr><tr><td align="center" rowspan="1" colspan="1">Duration of CPB</td><td align="center" rowspan="1" colspan="1">94 [79&#x02013;112]</td><td align="center" rowspan="1" colspan="1">88 [74-105]</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Valve surgery</td><td align="center" rowspan="1" colspan="1">196 (39)</td><td align="center" rowspan="1" colspan="1">289 (36)</td><td align="center" rowspan="1" colspan="1">0.377</td></tr></tbody></table></table-wrap>
</p><p>Patients in the DEX group were younger (54.7&#x000b1;13.2 years <italic>vs.</italic>
56.5&#x000b1;13.1 years, <italic>P</italic>=0.013) and had a lower additive EuroSCORE
(3; 1-4 <italic>vs.</italic> 3; 2-5, <italic>P</italic>&#x0003c;0.001) than patients in
the CON group. More patients in the CON group (83%) underwent on-pump surgery than
in the DEX group (77%) (<italic>P</italic>=0.011). Time on CPB was longer in the CON
group (94 minutes) than in the DEX group (88 minutes) (<italic>P</italic>&#x0003c;0.001)
(<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>ICU length of stay was significantly shorter for patients in the DEX group
(3.7&#x000b1;4.4 days) than for patients in the CON group (4.4&#x000b1;6.3 days)
(<italic>P</italic>=0.02). Thirty-day hospital mortality rates were 3.4% in the
DEX group and 9.7% in the CON group (<italic>P</italic>&#x0003c;0.001) (<xref ref-type="table" rid="t2">Table 2</xref>).</p><p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Outcome parameters in the study groups.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>CON group (n=506)</bold></th><th align="center" rowspan="1" colspan="1"><bold>DEX group (n=796)</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Reintubation</td><td align="center" rowspan="1" colspan="1">58 (11.0)</td><td align="center" rowspan="1" colspan="1">67 (8.4)</td><td align="center" rowspan="1" colspan="1">0.069</td></tr><tr><td rowspan="1" colspan="1">Need for reoperation</td><td align="center" rowspan="1" colspan="1">10 (2.0)</td><td align="center" rowspan="1" colspan="1">22 (2.8)</td><td align="center" rowspan="1" colspan="1">0.371</td></tr><tr><td rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">47 (9.3)</td><td align="center" rowspan="1" colspan="1">52 (6.5)</td><td align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td rowspan="1" colspan="1">Acute kidney injury</td><td align="center" rowspan="1" colspan="1">135 (27.0)</td><td align="center" rowspan="1" colspan="1">190 (24.0)</td><td align="center" rowspan="1" colspan="1">0.253</td></tr><tr><td rowspan="1" colspan="1">Type 1 neurological injury</td><td align="center" rowspan="1" colspan="1">24 (4.7)</td><td align="center" rowspan="1" colspan="1">16 (2.0)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">ICU readmission</td><td align="center" rowspan="1" colspan="1">28 (5.5)</td><td align="center" rowspan="1" colspan="1">28 (3.5)</td><td align="center" rowspan="1" colspan="1">0.081</td></tr><tr><td rowspan="1" colspan="1">ICU LOS (days); mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">4.4&#x000b1;6.3</td><td align="center" rowspan="1" colspan="1">3.7&#x000b1;4.4</td><td align="center" rowspan="1" colspan="1">0.020</td></tr><tr><td rowspan="1" colspan="1">30-day hospital mortality rates</td><td align="center" rowspan="1" colspan="1">49 (9.7)</td><td align="center" rowspan="1" colspan="1">27 (3.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ICU=intensive care unit; LOS=length of stay; SD=standard
deviation</p></fn></table-wrap-foot></table-wrap>
</p><p>The Kaplan-Meier survival curves for the DEX and CON groups are shown in <xref ref-type="fig" rid="f1">Figure 1</xref> (log-rank and Wilcoxon =
<italic>P</italic>&#x0003c;0.001). Results from the multivariable logistic regression
analysis with death as the dependent variable are shown in <xref ref-type="table" rid="t3">Table 3</xref>. Use of dexmedetomidine was independently associated
with a lower risk of 30-day mortality OR=0.39, 95% confidence interval (CI):
0.24-0.65, <italic>P</italic>&#x02264;0.001). The Logistic EuroSCORE (OR=1.05, 95%
CI: 1.02-1.10, <italic>P</italic>=0.004) and age (OR=1.03, 95% CI: 1.01-1.06,
<italic>P</italic>=0.003) were independently associated with a higher risk of
30-day mortality.</p><p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Multivariable logistic regression analysis with 30-day hospital mortality
as the dependent variable.</p></caption><table frame="box" rules="all" style="border-right:hidden;border-left:hidden"><colgroup span="1"><col width="33%" span="1"/><col width="34%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>Odds ratio CI (95%):</bold></th><th align="center" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Dexmedetomidine</td><td align="center" rowspan="1" colspan="1">0.39 (0.24-0.65)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Logistic EuroSCORE</td><td align="center" rowspan="1" colspan="1">1.05 (1.02-1.10)</td><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">Age (per year)</td><td align="center" rowspan="1" colspan="1">1.03 (1.01-1.06)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">Gender (Male <italic>vs</italic>. Female)</td><td align="center" rowspan="1" colspan="1">0.71 (0.43-1.18)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">CABG <italic>vs</italic>. Valve</td><td align="center" rowspan="1" colspan="1">0.65 (0.36-1.17)</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">1.19 (0.66-2.16)</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td rowspan="1" colspan="1">Left ventricular dysfunction</td><td align="center" rowspan="1" colspan="1">1.31 (0.74-2.3)</td><td align="center" rowspan="1" colspan="1">0.35</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CABG=coronary artery bypass graft surgery; CI=confidence interval</p><p>Hosmer and Lemeshow Chi square = 10.3 (<italic>P</italic>=0.244)</p><p>Nagelkerke R-square = 0.109</p></fn></table-wrap-foot></table-wrap>
</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Kaplan-Meier survival curves.</p></caption><graphic xlink:href="rbccv-31-03-0213-g01"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The main finding of this study in a large cohort of cardiac surgery patients is that
use of dexmedetomidine, an &#x003b1;-<sub>2</sub>-agonist, as an anesthetic adjuvant
was independently associated with a lower risk of 30-day in-hospital death compared
to the CON group. In addition, patients receiving dexmedetomidine spent less time in
the ICU and had a lower frequency of type 1 neurological lesions.</p><p>The reasons for the better outcomes are not known, but is likely to be related to the
blunting of stress response, greater hemodynamic stability, sparing effect on oxygen
consumption, protection of perioperative ischemia and preservation of neutrophil/
cellular immune function reported with the use of dexmedetomidine in comparison to
opioids<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p><p>Accordingly, Wijeysundera et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> performed a systematic review of studies evaluating the use of
&#x003b1;-<sub>2</sub>-agonists (clonidine, dexmedetomidine or mivazerol)
perioperatively for the prevention of cardiac complications among patients
undergoing surgery. Overall, &#x003b1;-<sub>2</sub>-adrenergic agonists were
associated with a more than 50% reduction in mortality in vascular surgery patients,
in addition to reductions in cardiac mortality and myocardial infarction. Even when
initiated after CBP infusion of dexmedetomidine was associated with decreased
postoperative mortality up to 1 year and decreased incidence of postoperative
complications and delirium in patients undergoing cardiac surgery<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. In children undergoing complex
congenital heart disease the use of dexmedetomidine after anesthesia induction was
associated with less variability in heart rate and blood pressure than with the use
of propofol<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p><p>We found a decreased incidence of neurological problems in the DEX group in
univariate analysis. The possibility of neuroprotection is speculative and should be
tested prospectively. It has been suggested that &#x003b1;-<sub>2</sub>-adrenergic
agonists improve neurological deficit scores and reduce infarct sizes in cerebral
ischemia. These agonists improved the histomorphological and neurological outcomes
after cerebral ischemic injury when administered during ischemia, and recent studies
have provided considerable evidence that &#x003b1;-<sub>2</sub>-adrenergic agonists
can protect the brain from ischemia/ reperfusion injury<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. The mechanisms by which
&#x003b1;-<sub>2</sub>-adrenergic agonists exert their neuroprotective effects are
still unclear in humans since almost all studies regarding the neuroprotective
effects of dexmedetomidine have been performed in animals<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> or <italic>in vitro</italic><sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Sulemanji et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> demonstrated no benefit of
dexmedetomidine as a neuroprotective agent during CABG surgery. Nevertheless, the
use of dexmedetomidine as sedative agent in critically ill patients is associated
with reduction in the incidence of delirium<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. It is possible that the hemodynamic stability provided by
dexmedetomidine may have favorable effects on the maintenance of cerebral
perfusion<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Older age and the CPB time were associated with a higher risk of death in our study.
The increased morbidity and mortality seen in elderly patients after cardiac
surgical procedures is due to biological aging processes, but also to greater
disease severity, associated comorbidities and surgical urgency than in younger
patients<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Widyastuti et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> identified older age as predictor
of prolonged mechanical ventilation following cardiac surgery. Older patients also
have twice the incidence of postoperative stroke<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Both, older age and CPB time are linked to
neurological dysfunction because of the augmented risk for microvascular cerebral
obstruction and decline neurocognitive function<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p><p>The present study has some important limitations; particularly its retrospective
nature with potential bias. The heterogeneity in the baseline status of the groups
regarding age, EuroSCORE and CPB time, are all likely to be related to worse
outcomes. The CON group had a higher mortality than it is expected on the
literature. The EuroSCORE prognostic index did not reflect the mortality rate seen
in this group, but it is not known if it is an applicable tool to our system of
care. The agreement between the predict mortality by the EuroSCORE has been
questioned by different centers in Brazil with conflicting results<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>]</sup>, therefore a weight adjustment factor could probably
correct its performance. In addition, the hospital where the study was performed is
a reference in public health care system, being responsible to treat the most severe
cases of a population that does not have access to primary health care. Indeed, the
long observation period also carries a risk of other variables to be involved on the
results. We corrected for a large number of possible confounders by performing a
multivariate analysis, but it is possible that other, unknown, confounders were
still present. Complications were analyzed at a univariate level; therefore a
cause-effect relationship cannot be definitely established.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Dexmedetomidine used as an anesthetic adjuvant was associated with better outcomes in
patients undergoing CABG and valve surgery. Randomized prospective controlled trials
are warranted to confirm our results.</p><p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Authors' roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">PGMB</td><td rowspan="1" colspan="1">Realization of operations and/or trials; final manuscript
approval</td></tr><tr><td rowspan="1" colspan="1">FRL</td><td rowspan="1" colspan="1">Manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td rowspan="1" colspan="1">SLR</td><td rowspan="1" colspan="1">Manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td rowspan="1" colspan="1">YS</td><td rowspan="1" colspan="1">Statistical analysis; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">MNM</td><td rowspan="1" colspan="1">Conception and design study; analysis and/or data
interpretation; manuscript redaction or critical review of its
content; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">SML</td><td rowspan="1" colspan="1">Conception and design study; analysis and/or data
interpretation; manuscript redaction or critical review of its
content; final manuscript approval</td></tr></tbody></table></table-wrap>
</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the S&#x000e3;o Jos&#x000e9; do Rio Preto Medical School (FAMERP),
Hospital de Base de S&#x000e3;o Jos&#x000e9; do Rio Preto (HB), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP,
Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>E</given-names></name><name><surname>Hallowell</surname><given-names>P</given-names></name><name><surname>Levine</surname><given-names>FH</given-names></name><name><surname>Daggett</surname><given-names>WM</given-names></name><name><surname>Austen</surname><given-names>WG</given-names></name><name><surname>Laver</surname><given-names>MB</given-names></name></person-group><article-title>Cardiovascular response to large doses of intravenous morphine in
man</article-title><source>N Engl J Med</source><year>1969</year><volume>281</volume><issue>25</issue><fpage>1389</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">5355454</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>DC</given-names></name><name><surname>Wall</surname><given-names>C</given-names></name><name><surname>Djaiani</surname><given-names>G</given-names></name><name><surname>Peragallo</surname><given-names>RA</given-names></name><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Randomized assessment of resources use in fast-track cardiac
surgery 1-year after hospital discharge</article-title><source>Anesthesiology</source><year>2003</year><volume>98</volume><issue>3</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">12606909</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>A</given-names></name><name><surname>Vega</surname><given-names>G</given-names></name><name><surname>Blancas</surname><given-names>R</given-names></name><name><surname>Morat&#x000f3;</surname><given-names>B</given-names></name><name><surname>Moreno</surname><given-names>JL</given-names></name><name><surname>Torrecilla</surname><given-names>C</given-names></name><etal/></person-group><article-title>Early vs. conventional extubation after cardiac surgery with
cardiopulmonary bypass</article-title><source>Chest</source><year>1997</year><volume>112</volume><issue>1</issue><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">9228376</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myles</surname><given-names>PS</given-names></name><name><surname>Daly</surname><given-names>DJ</given-names></name><name><surname>Djaiani</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>DC</given-names></name></person-group><article-title>A systematic review of the safety and effectiveness of fast-track
cardiac anesthesia</article-title><source>Anesthesiology</source><year>2003</year><volume>99</volume><issue>4</issue><fpage>982</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">14508335</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svircevic</surname><given-names>V</given-names></name><name><surname>Nierich</surname><given-names>AP</given-names></name><name><surname>Moons</surname><given-names>KG</given-names></name><name><surname>Brandon Bravo Bruinsma</surname><given-names>GJ</given-names></name><name><surname>Kalkman</surname><given-names>CJ</given-names></name><name><surname>van Dijk</surname><given-names>D</given-names></name></person-group><article-title>Fast-track anesthesia and cardiac surgery: a retrospective cohort
study of 7989 patients</article-title><source>Anesth Analg</source><year>2009</year><volume>108</volume><issue>3</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">19224776</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talke</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>B</given-names></name><name><surname>Aggarwall</surname><given-names>A</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Thorborg</surname><given-names>P</given-names></name><etal/></person-group><article-title>The hemodynamic and adrenergic effects of perioperative
dexmedetomidine infusion after vascular surgery</article-title><source>Anesth Analg</source><year>2000</year><volume>90</volume><issue>4</issue><fpage>834</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">10735784</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>MS</given-names></name><name><surname>Erkola</surname><given-names>OA</given-names></name><name><surname>Scheinin</surname><given-names>H</given-names></name><name><surname>Lehtinen</surname><given-names>AM</given-names></name><name><surname>Korttila</surname><given-names>KT</given-names></name></person-group><article-title>Effect of intravenously administered dexmedetomidine on pain
after laparoscopic tubal ligation</article-title><source>Anesth Analg</source><year>1991</year><volume>73</volume><issue>2</issue><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">1854025</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riker</surname><given-names>RR</given-names></name><name><surname>Shehabi</surname><given-names>Y</given-names></name><name><surname>Bokesch</surname><given-names>PM</given-names></name><name><surname>Ceraso</surname><given-names>D</given-names></name><name><surname>Wisemandle</surname><given-names>W</given-names></name><name><surname>Koura</surname><given-names>F</given-names></name><etal/><collab>SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With
Midazolam) Study Group</collab></person-group><article-title>Dexmedetomidine vs. midazolam for sedation of critically ill
patients: a randomized trial</article-title><source>JAMA</source><year>2009</year><volume>301</volume><issue>5</issue><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">19188334</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herr</surname><given-names>DL</given-names></name><name><surname>Sum-Ping</surname><given-names>ST</given-names></name><name><surname>England</surname><given-names>M</given-names></name></person-group><article-title>ICU sedation after coronary artery bypass graft surgery:
exmedetomidine-based versus propofol-based sedation regimens</article-title><source>J Cardiothorac Vasc Anesth</source><year>2003</year><volume>17</volume><issue>5</issue><fpage>576</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">14579210</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalonen</surname><given-names>J</given-names></name><name><surname>Hynynen</surname><given-names>M</given-names></name><name><surname>Kuitunen</surname><given-names>A</given-names></name><name><surname>Heikkil&#x000e4;</surname><given-names>H</given-names></name><name><surname>Perttil&#x000e4;</surname><given-names>J</given-names></name><name><surname>Salmenper&#x000e4;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dexmedetomidine as an anesthetic adjunct in coronary artery
bypass grafting</article-title><source>Anesthesiology</source><year>1997</year><volume>86</volume><issue>2</issue><fpage>331</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">9054252</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Miranda</surname><given-names>RC</given-names></name><name><surname>Takakura</surname><given-names>IT</given-names></name><name><surname>Palmegiani</surname><given-names>E</given-names></name><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Oliveira</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Acute kidney injury after on-pump coronary artery bypass graft
surgery</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>3</issue><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">19851652</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Salamon</surname><given-names>R</given-names></name></person-group><article-title>European system for cardiac operative risk evaluation
(EuroSCORE)</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>16</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10456395</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Palevsky</surname><given-names>P</given-names></name><collab>Acute Dialysis Quality Initiative workgroup</collab></person-group><article-title>Acute renal failure - definition, outcome measures, animal
models, fluid therapy and information technology needs: the Second
International Consensus Conference of the Acute Dialysis Quality Initiative
(ADQI) Group</article-title><source>Crit Care</source><year>2004</year><volume>8</volume><issue>4</issue><fpage>R204</fpage><lpage>R212</lpage><pub-id pub-id-type="pmid">15312219</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>AW</given-names></name><name><surname>Galindez</surname><given-names>D</given-names></name><name><surname>Salahieh</surname><given-names>A</given-names></name><name><surname>Layug</surname><given-names>EL</given-names></name><name><surname>Lazo</surname><given-names>EA</given-names></name><name><surname>Haratonik</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Effect of clonidine on cardiovascular morbidity and mortality
after noncardiac surgery</article-title><source>Anesthesiology</source><year>2004</year><volume>101</volume><issue>2</issue><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">15277909</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halter</surname><given-names>JB</given-names></name><name><surname>Pflug</surname><given-names>AE</given-names></name><name><surname>Porte</surname><given-names>D</given-names><suffix>Jr</suffix></name></person-group><article-title>Mechanism of plasma catecholamine increases during surgical
stress in man</article-title><source>J Clin Endocrinol Metab</source><year>1977</year><volume>45</volume><issue>5</issue><fpage>936</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">925142</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><name><surname>Bender</surname><given-names>JS</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name></person-group><article-title>Alpha-2 adrenergic agonists for the prevention of cardiac
complications among patients undergoing surgery</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><issue>4</issue><fpage>CD004126</fpage><lpage>CD004126</lpage><pub-id pub-id-type="pmid">19821319</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Fleming</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Perioperative dexmedetomidine improves outcomes of cardiac
surgery</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>15</issue><fpage>1576</fpage><lpage>1584</lpage><pub-id pub-id-type="pmid">23513068</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of the effects of dexmedetomidine and propofol on
hemodynamics and oxygen balance in children with complex congenital heart
disease undergoing cardiac surgery</article-title><source>Congenit Heart Dis</source><year>2015</year><volume>10</volume><issue>3</issue><fpage>E123</fpage><lpage>E130</lpage><pub-id pub-id-type="pmid">25346460</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kimelberg</surname><given-names>HK</given-names></name></person-group><article-title>Neuroprotection by alpha 2-adrenergic agonist in cerebral
ischemia</article-title><source>Curr Neuropharmacol</source><year>2005</year><volume>3</volume><issue>4</issue><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">18369397</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>BR</given-names></name><name><surname>L&#x000f6;berg</surname><given-names>EM</given-names></name><name><surname>Steen</surname><given-names>PA</given-names></name></person-group><article-title>Dexmedetomidine, a potent alpha 2-agonist, does not affect
neuronal damage following severe forebrain ischaemia in the
rat</article-title><source>Eur J Anesthesiol</source><year>1995</year><volume>12</volume><issue>3</issue><fpage>281</fpage><lpage>285</lpage></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>AC</given-names></name><name><surname>Hertz</surname><given-names>L</given-names></name></person-group><article-title>Dexmedetomidine-induced stimulation of glutamine oxidation in
astrocytes: a possible mechanism for its neuroprotective
activity</article-title><source>J Cereb Blood Flow Metab</source><year>2000</year><volume>20</volume><issue>6</issue><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">10894172</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulemanji</surname><given-names>DS</given-names></name><name><surname>D&#x000f6;nmez</surname><given-names>A</given-names></name><name><surname>Aldemir</surname><given-names>D</given-names></name><name><surname>Sezgin</surname><given-names>A</given-names></name><name><surname>T&#x000fc;rkoglu</surname><given-names>S</given-names></name></person-group><article-title>Dexmedetomidine during coronary artery bypass grafting surgery:
is it neuroprotective? A preliminary study</article-title><source>Acta Anesthesiol Scand</source><year>2007</year><volume>51</volume><issue>8</issue><fpage>1093</fpage><lpage>1098</lpage></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Momon</surname><given-names>A</given-names></name><name><surname>Mantz</surname><given-names>J</given-names></name><name><surname>Payen</surname><given-names>JF</given-names></name><name><surname>De Jonghe</surname><given-names>B</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of sedation with dexmedetomidine in critical
care patients: a meta-analysis of randomized controlled
trials</article-title><source>Anaesth Crit Care Pain Med</source><year>2016</year><volume>35</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">26700947</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>KP</given-names></name><name><surname>Anstrom</surname><given-names>KJ</given-names></name><name><surname>Muhlbaier</surname><given-names>LH</given-names></name><name><surname>Grosswald</surname><given-names>RD</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Jones</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Outcomes of cardiac surgery in patients &#x0003e; or = 80 years:
results from the National Cardiovascular Network</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><issue>3</issue><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">10716477</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortasawi</surname><given-names>A</given-names></name><name><surname>Arnrich</surname><given-names>B</given-names></name><name><surname>Rosendahal</surname><given-names>U</given-names></name><name><surname>Frerichs</surname><given-names>I</given-names></name><name><surname>Albert</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><etal/></person-group><article-title>Is age an independent determinant of mortality in cardiac surgery
as suggested by the EuroSCORE?</article-title><source>BMC Surg</source><year>2002</year><volume>2</volume><fpage>8</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12370083</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widyastuti</surname><given-names>Y</given-names></name><name><surname>Stenseth</surname><given-names>R</given-names></name><name><surname>Pleym</surname><given-names>H</given-names></name><name><surname>Wahba</surname><given-names>A</given-names></name><name><surname>Videm</surname><given-names>V</given-names></name></person-group><article-title>Pre-operative and intraoperative determinants for prolonged
ventilation following adult cardiac surgery</article-title><source>Acta Anaesthesiol Scand</source><year>2012</year><volume>56</volume><issue>2</issue><fpage>190</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">22091558</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrowsmith</surname><given-names>JE</given-names></name><name><surname>Grocott</surname><given-names>HP</given-names></name><name><surname>Reves</surname><given-names>JG</given-names></name><name><surname>Newman</surname><given-names>MF</given-names></name></person-group><article-title>Central nervous system complications of cardiac
surgery</article-title><source>Br J Anaesth</source><year>2000</year><volume>84</volume><issue>3</issue><fpage>378</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">10793601</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>MR</given-names></name><name><surname>Souza e Silva</surname><given-names>NA</given-names></name><name><surname>Klein</surname><given-names>CH</given-names></name><name><surname>Oliveira</surname><given-names>GM</given-names></name></person-group><article-title>Application of the EuroSCORE in coronary artery bypass surgery in
public hospitals in Rio de Janeiro, Brazil</article-title><source>Rev Bras Cir Cardiovasc</source><year>2010</year><volume>25</volume><issue>2</issue><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">20802913</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campagnucci</surname><given-names>VP</given-names></name><name><surname>Pinto e Silva</surname><given-names>AM</given-names></name><name><surname>Pereira</surname><given-names>WL</given-names></name><name><surname>Chamlian</surname><given-names>EG</given-names></name><name><surname>Gandra</surname><given-names>SM</given-names></name><name><surname>Rivetti</surname><given-names>LA</given-names></name></person-group><article-title>EuroSCORE and the patients undergoing coronary bypass surgery at
Santa Casa de S&#x000e3;o Paulo</article-title><source>Rev Bras Cir Cardiovasc</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">18820791</pub-id></element-citation></ref></ref-list></back></article>